View Author
patient polymorphism restenosi study -10 revascularization strategy syndrome netherland haplotype factor analysis il -10 gene association center treatment effect leiden allele result genotype death cardiology stent event randomized table follow-up heart department level group disease il -10 polymorphisms p 2y gene trial diabetes frequency university plasminogen activator inhibitor target vessel revascularization signi in-hospital revascularization 298asp glu 298asp polymorphism nos 3 polymorphisms leiden university artery revascularized procedure in-hospital nitric -949 regression outcome 4 years il -10 mortality oxide nos 3 gene 3 years month intervention vessel platelet population randomized treatment strategy treatment strategy signi ficance ictus trial endpoint protein region signi ficant cad p 2y haplotypes glu 298asp polymorphisms þ 4259 -716 genotyping tvr risk
6 Most Recent Publications
|
Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody coated stent (Genous™Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients
(Article)
Dekker, W. den Houtgraaf, J. Rowland, S.M. Ligtenberg, E. Hill, J. Wiemer, M. Heijer, P. den Rensing, B.J.W.M. Channon, K.M. Serruys, P.W.J.C. Duckers, H.J. Onuma, Y. Benit, E. Winter, R.J. de Wijns, W. Grisold, M. Verheye, S. Silber, S. Teiger, E. |
2011-11-01
|
|
Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndrome
(Article)
Pons, D. Monraats, P.S. Zwinderman, A.H. Maat, M.P.M. de Doevendans, P.A. Winter, R.J. de Tio, R.A. Waltenberger, J. Jukema, J.W. |
2009-07-31
|
|
Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: The problem of treatment selection bias
(Article)
Hirsch, A. Windhausen, F. Tijssen, J.G.P. Oude Ophuis, A.J.M. Giessen, W.J. van der Zee, P.M. van der Cornel, J.H. Verheugt, F.W.A. Winter, R.J. de |
2009-03-01
|
|
Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions
(Article)
Rudež, G. Pons, D. Jukema, J.W. Leebeek, F.W.G. Monraats, P.S. Schrevel, M. Zwinderman, A.H. Winter, R.J. de Tio, R.A. Doevendans, P.A. Maat, M.P.M. de |
2008-03-01
|
|
The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions
(Article)
Pons, D. Monraats, P.S. Winter, R.J. de Tio, R.A. Frants, R.R. Laarse, A. van der Wall, E.E. van der Jukema, J.W. Maat, M.P.M. de Pires, N.M.M. Quax, P.H.A. Vlijmen, B.J.M. van Rosendaal, F.R. Zwinderman, A.H. Doevendans, P.A. Waltenberger, J. |
2007-12-01
|
|
Interleukin 10: A new risk marker for the development of restenosis after percutaneous coronary intervention
(Article)
Monraats, P.S. Kurreeman, F.A.S. Waltenberger, J. Huizinga, T.W.J. Eefting, D. Quax, P.H.A. Frants, R.R. Laarse, A. van der Wall, E.E. van der Jukema, J.W. Pons, D. Sewgobind, V.D.K.D. Vries, F.R. de Zwinderman, A.H. Maat, M.P.M. de Doevendans, P.A. Winter, R.J. de Tio, R.A. |
2007-01-01
|